None listed
Conditions
Brief summary
The primary purpose of this study is to evaluate whether acute supplementation with either of two nutraceutical combination formulas (ErgGo Mom and ErgGo POP), relative to placebo, reduces self-rated mental fatigue associated with performing cognitively demanding tasks.
Interventions
Investigational products will be administered once orally (with approximately 1 week wash-out between investigational products). Participants will consume a different treatment each testing day. Each product consists of a powdered drink mix, which is to be dissolved in 500ml of water prior to consumption.
The intervention will be consumed at the testing centre by healthy volunteers while under researcher supervision
The following products will be investigated:
ErgGo MOM contains:
Green tea ex
Investigational products will be administered once orally (with approximately 1 week wash-out between investigational products). Participants will consume a different treatment each testing day. Each product consists of a powdered drink mix, which is to be dissolved in 500ml of water prior to consumption. The intervention will be consumed at the testing centre by healthy volunteers while under researcher supervision The following products will be investigated: ErgGo MOM contains: Green tea extract (130mg including 13mg of caffeine) Quercetin (100mg) Enzogenol (50mg) Magnesium (50mg) L-Theanine (25mg) Niacin (20mg) Vitamin B6 (2mg) Vitamin B12 (400mcg) Maltodextrin plus stevia (sweetener) and natural flavour/colour Citric Acid, Gum Acacia, Guar Gum, Xanthan Gum ErgGo POP contains: DMAE (dimethylaminoethanol, 200mg) Green tea extract (130mg including 13mg of caffeine) Quercetin (100mg) Caffeine (87mg) Enzogenol (50mg) Magnesium (50mg) L-Theanine (25mg) Niacin (20mg) Vitamin B6 (2mg) Vitamin B12 (400mcg) Maltodextrin plus stevia (sweetener) and natural flavour/colour Citric Acid, Gum Acacia, Guar Gum, Xanthan Gum
Sponsors
Swinburne University of Technology
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy adults aged 20 to 50 years
Exclusion criteria
Participant experiences or evidence of delirium, confusion, or other disturbance of consciousness. Participant has any diagnosed illness or disorder affecting cognitive function or mood such as depression, anxiety, stroke or dementia. Individuals currently taking prescription medication other than a contraceptive pill. Any significant concurrent illness including any bleeding disorders, coronary heart disease, diabetes, gastrointestinal disorder. Any known or suspected food allergies (this would cover all ingredients in the investigational product). Participant has a recent history of (within 12 months of V1) or strong potential for alcohol or substance abuse. Participant is a female, who is pregnant, planning to be pregnant during the study period, or lactating.
Outcome results
None listed